Barinthus Biotherapeutics PLC. 8-K Filing
Ticker: BRNS · Form: 8-K · Filed: Dec 10, 2025 · CIK: 1828185
| Field | Detail |
|---|---|
| Company | Barinthus Biotherapeutics PLC. (BRNS) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2025 |
| Pages | 4 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Barinthus Biotherapeutics PLC. (ticker: BRNS) to the SEC on Dec 10, 2025.
How long is this filing?
Barinthus Biotherapeutics PLC.'s 8-K filing is 4 pages with approximately 1,118 words. Estimated reading time is 4 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,118 words · 4 min read · ~4 pages · Grade level 13.4 · Accepted 2025-12-10 08:05:05
Filing Documents
- brns-20251210.htm (8-K) — 31KB
- brns-20251210xexx991.htm (EX-99.1) — 14KB
- a1a.jpg (GRAPHIC) — 5KB
- 0001828185-25-000075.txt ( ) — 221KB
- brns-20251210.xsd (EX-101.SCH) — 2KB
- brns-20251210_def.xml (EX-101.DEF) — 17KB
- brns-20251210_lab.xml (EX-101.LAB) — 29KB
- brns-20251210_pre.xml (EX-101.PRE) — 17KB
- brns-20251210_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On December 10, 2025, Barinthus Biotherapeutics plc (the "Company") issued a press release titled "Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease." A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing. Additional Information and Where to Find It In connection with the proposed transaction, the combined company filed with the Securities and Exchange Commission (the "SEC") a registration statement on Form S-4 that contains a proxy statement prospectus (the "Registration Statement") on November 7, 2025, to register the common stock in connection with the proposed transaction and intends to mail or otherwise provide the definitive Registration Statement to the Company's investors and security holders. THE COMPANY'S INVESTORS AND SECURITY HOLDERS ARE URGED TO CAREFULLY READ THE REGISTRATION STATEMENT IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE AND ANY OTHER DOCUMENTS FILED BY THE COMPANY WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. Investors and security holders may obtain a free copy of the Registration Statement and other documents that the combined company files with the SEC (when available) from the SEC's website at www.sec.gov or at investors.barinthusbio.com. Participants in the
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release dated December 10 , 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Barinthus Biotherapeutics plc Date: December 10, 2025 By: /s/ William Enright William Enright Chief Executive Officer